Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 0.63 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | NT5E | P21589 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | METAP2 | P50579 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29471057 | 1.00 | BACE1 (0.63) | BACE1HTTCYP1A2CYP2C19PABPC1 | |
| Isopropylamine SCHEMBL20480684 | 0.89 | BACE1 (0.56) | BACE1HTTCYP1A2CYP2C19PABPC1 | |
| Tert-Butylamine SCHEMBL20480686 | 0.89 | BACE1 (0.56) | BACE1HTTCYP1A2CYP2C19PABPC1 | |
| SCHEMBL20480661 | 0.87 | BACE1 (0.55) | BACE1HTTCYP1A2CYP2C19PABPC1 | |
| SCHEMBL789486 | 0.84 | BACE1 (0.64) | BACE1HTTCYP1A2CYP2C19PABPC1 | |
| SCHEMBL20480449 | 0.84 | BACE1 (0.51) | BACE1HTTCYP1A2CYP2C19PABPC1 | |
| Cyclopentanamine SCHEMBL20480640 | 0.83 | BACE1 (0.50) | BACE1HTTCYP1A2CYP2C19PABPC1 | |
| SCHEMBL18317038 | 0.77 | BACE1 (1.00) | BACE1HTTCYP1A2CYP2C19PABPC1 | |
| SCHEMBL29612580 | 0.77 | BACE1 (1.00) | BACE1HTTCYP1A2CYP2C19PABPC1 | |
| SCHEMBL2133059 | 0.76 | NR4A2 (0.54) | BACE1CYP1A2CYP2A6MAPTNOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 202 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009002955-A1 | PROCESS FOR THE PREPARATION OF (2R)-2-[4-(7-BROMO-2-QUINOLYLOXY)PHENOXY]PROPANOIC ACID | SANOFI-AVENTIS U.S. LLC (US) | 2008-12-31 | — | — | WO | claimed |
| EP-4745212-A1 | NEW COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME | TOP RUN MATERIAL SOLUTION Co., Ltd. (KR) | 2026-05-20 | — | — | EP | disclosed |
| CN-122036721-A | Novel compound and organic light emitting device comprising the same | 株式会社进雄产业 | 2026-05-15 | — | — | CN | disclosed |
| US-20260136757-A1 | NEW COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME | TOP RUN MAT SOLUTION CO LTD (KR) | 2026-05-14 | — | — | US | disclosed |
| US-20250243219-A1 | MACROCYCLIC COMPOUNDS AND USES THEREOF | CYPRALIS LIMITED (GB) | 2025-07-31 | — | — | US | disclosed |
| EP-4583874-A1 | MULTITARGET NUCLEAR RECEPTOR LIGANDS BASED ON 2-(4-(QUINOLIN-2-YLOXY)PHENOXY)PROPANOIC ACID AND 2-(4-(QUINOXALIN-2-YLOXY)PHENOXY)PROPANOIC ACID FOR THE TREATMENT OF METABOLIC AND LIVER DISEASES | CHARLES UNIVERSITY, FACULTY OF PHARMACY IN HRADEC KRALOVE (CZ) | 2025-07-16 | — | — | EP | disclosed |
| EP-4548972-A2 | (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE I INHIBITORS | AstraZeneca AB (SE) | 2025-05-07 | — | — | EP | disclosed |
| US-20250109148-A1 | HETEROCYCLIC GLP-1 AGONISTS | SHANGHAI SHOUTI BIOTECHNOLOGY CO., LTD. (CN) | 2025-04-03 | — | — | US | disclosed |
| EP-4526308-A1 | MACROCYCLIC COMPOUNDS AND USES THEREOF | Cypralis Limited (GB) | 2025-03-26 | — | — | EP | disclosed |
| EP-3833668-B1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2025-03-19 | — | — | EP | disclosed |
| WO-2009002955-A1 | PROCESS FOR THE PREPARATION OF (2R)-2-[4-(7-BROMO-2-QUINOLYLOXY)PHENOXY]PROPANOIC ACID | SANOFI-AVENTIS U.S. LLC (US) | 2008-12-31 | — | — | WO | disclosed |
| CN-101243068-A | Compounds for the treatment of multi-drug resistant bacterial infections | ASTRAZENECA AB (SE) | 2008-08-13 | — | — | CN | disclosed |
| WO-2008071961-A1 | 2-QUINOLINONE AND 2-QUINOXALINONE- DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | ASTRAZENECA AB (SE) | 2008-06-19 | — | — | WO | disclosed |
| EP-1893599-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | AstraZeneca AB (SE) | 2008-03-05 | — | — | EP | disclosed |
| US-20080045521-A1 | PHENYLALANINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | US | disclosed |
| US-20080045521-A1 | PHENYLALANINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | US | disclosed |
| US-20080045521-A1 | PHENYLALANINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | US | disclosed |
| WO-2007141473-A1 | N-(BENZOYL)-O- [2- (PYRIDIN- 2 -YLAMINO) ETHYL] -L-TYROSINE DERIVATIVES AND RELATED COMPOUNDS AS A5B1 ANTAGONISTS FOR THE TREATMENT OF SOLID TUMORS | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | WO | disclosed |
| WO-2006134378-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2006-12-21 | — | — | WO | disclosed |
| US-5372813-A | Measurement of serotonin uptake sites in a sample using a radio labeled substituted 6-nitroquipazine as a radioligand | THE REGENTS, UNIVERSITY OF CALIFORNIA (US) | 1994-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045521-A1 | PHENYLALANINE DERIVATIVES | ITGB5, ITGB1, ITGA2B | BACE1 3634/4885HTT 3990/4885CYP1A2 3894/4885 |
| US-20250109148-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | BACE1 752/4885HTT 250/4885CYP1A2 2014/4885 |
| US-20260136757-A1 | NEW COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME | CCNL2, TBL3, HBS1L | BACE1 1789/4885HTT 3755/4885CYP1A2 738/4885 |
| US-20250243219-A1 | MACROCYCLIC COMPOUNDS AND USES THEREOF | CASP3, TNNC1, BAD | BACE1 404/4885HTT 504/4885CYP1A2 2413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.